50th anniversary of cisplatin

被引：47

作者：

Rancoule, Chloe ^{[1
,2
]}

Guy, Jean-Baptiste ^{[1
,2
]}

Vallard, Alexis ^{[1
]}

Ben Mrad, Majed ^{[1
]}

Rehailia, Amel ^{[1
]}

Magne, Nicolas ^{[1
,2
]}

机构：

[1] Inst Cancerol Lucien Neuwirth, Dept Radiotherapie, 108 Bis,Ave Albert Raimond,BP 60008, F-42271 St Priest En Jarez, France

[2] CNRS UMR 5822, Lab Radiobiol Cellulaire & Mol Lyon Sud, 165 Chemin Grand Revoyet,BP 12, F-69921 Oullins, France

来源：

BULLETIN DU CANCER | 2017年 / 104卷 / 02期

关键词：

Cisplatin; Chemotherapy; Carboplatin; Oxaliplatin; Resistance; Toxicities; CELL LUNG-CANCER; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; ADENOSINE-TRIPHOSPHATASE ATP7B; ANTICANCER DRUG CISPLATIN; ADVANCED OVARIAN-CANCER; MOLECULAR-MECHANISMS; PLATINUM COMPOUNDS; RADIATION-THERAPY; TUMOR RESPONSE; TREATMENT TIME;

D O I：

10.1016/j.bulcan.2016.11.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We have just celebrated the 50th anniversary of cisplatin cytotoxic potential discovery. It is time to take stock... and it seems mainly positive. This drug, that revolutionized the treatment of many cancer types, continues to be the most widely prescribed chemotherapy. Despite significant toxicities, resistance mechanisms associated with treatment failures, and unresolved questions about its mechanism of action, the use of this cytotoxic agent remains unwavering. The interest concerning this "old'' invincible drug has not yet abated. Indeed many research axes are in the news. New platinum salts agents are tested, new cisplatin formulations are developed to target tumor cells more efficiently, and new combinations are established to increase the cytotoxic potency of cisplatin or overcome the resistance mechanisms.

引用

页码：167 / 176

页数：10

共 87 条

[1] Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 39 randomized trials [J].

Aabo, K ;

Adams, M ;

Adnitt, P ;

Alberts, DS ;

Athanazziou, A ;

Barley, V ;

Bell, DR ;

Bianchi, U ;

Bolis, G ;

Brady, MF ;

Brodovsky, HS ;

Bruckner, H ;

Buyse, M ;

Canetta, R ;

Chylak, V ;

Cohen, CJ ;

Colombo, N ;

Conte, PF ;

Crowther, D ;

Edmonson, JH ;

Gennatas, C ;

Gilbey, E ;

Gore, M ;

Guthrie, D ;

Kaye, SB ;

Laing, AH ;

Landoni, F ;

Leonard, RC ;

Lewis, C ;

Liu, PY ;

Mangioni, C ;

Marsoni, S ;

Meerpohl, H ;

Omura, GA ;

Parmar, MKB ;

Pater, J ;

Pecorelli, S ;

Presti, M ;

Sauerbrei, W ;

Skarlos, DV ;

Smalley, RV ;

Solomon, HJ ;

Stewart, LA ;

Sturgeon, JFG ;

Tattersall, MHN ;

Wharton, JT ;

Huinink, WWT ;

Tomirotti, M ;

Torri, W ;

Trope, C .

BRITISH JOURNAL OF CANCER, 1998, 78 (11) :1479-1487

[2] Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review [J].

Ahn, Myung-Ju ;

D'Cruz, Anil ;

Vermorken, Jan B. ;

Chen, Jo-Pai ;

Chitapanarux, Imjai ;

Huy Quoc Thinh Dang ;

Guminski, Alex ;

Kannarunimit, Danita ;

Lin, Tong-Yu ;

Ng, Wai Tong ;

Park, Keon-Uk ;

Chan, Anthony Tak Cheung .

ORAL ONCOLOGY, 2016, 53 :10-16

[3] Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma [J].

Aida, T ;

Takebayashi, Y ;

Shimizu, T ;

Okamura, C ;

Higasimoto, M ;

Kanzaki, A ;

Nakayama, K ;

Terada, K ;

Sugiyama, T ;

Miyazaki, K ;

Ito, K ;

Takenoshita, S ;

Yaegashi, N .

GYNECOLOGIC ONCOLOGY, 2005, 97 (01) :41-45

[4] Elapsed radiation therapy treatment time as a predictor of survival in patients with advanced head and neck cancer who receive chemotherapy and radiation therapy [J].

Alden, ME ;

OReilly, RC ;

Topham, A ;

Lowry, LD ;

Brodovsky, H ;

Curran, WJ .

RADIOLOGY, 1996, 201 (03) :675-680

[5] Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer [J].

Ansaloni, L. ;

Coccolini, F. ;

Morosi, L. ;

Ballerini, A. ;

Ceresoli, M. ;

Grosso, G. ;

Bertoli, P. ;

Busci, L. M. ;

Lotti, M. ;

Cambria, F. ;

Pisano, M. ;

Rossetti, D. ;

Frigerio, L. ;

D'Incalci, M. ;

Zucchetti, M. .

BRITISH JOURNAL OF CANCER, 2015, 112 (02) :306-312

[6] The state-of-play and future of platinum drugs [J].

Apps, Michael G. ;

Choi, Eugene H. Y. ;

Wheate, Nial J. .

[7] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[8]

BAJORIN DF, 1986, CANCER RES, V46, P5969

[9] DNA UNWINDING PRODUCED BY SITE-SPECIFIC INTRASTRAND CROSS-LINKS OF THE ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II) [J].

BELLON, SF ;

COLEMAN, JH ;

LIPPARD, SJ .

BIOCHEMISTRY, 1991, 30 (32) :8026-8035

[10] Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA [J].

Berndtsson, Maria ;

Hagg, Maria ;

Panaretakis, Theocharis ;

Havelka, Aleksandra Mandic ;

Shoshan, Maria C. ;

Linder, Stig .

INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (01) :175-180

← 1 2 3 4 5 6 7 8 9 →